Traders Buy Sangamo Therapeutics (SGMO) on Weakness

Investors purchased shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) on weakness during trading on Thursday. $29.08 million flowed into the stock on the tick-up and $13.74 million flowed out of the stock on the tick-down, for a money net flow of $15.34 million into the stock. Of all stocks tracked, Sangamo Therapeutics had the 22nd highest net in-flow for the day. Sangamo Therapeutics traded down ($1.05) for the day and closed at $16.25

SGMO has been the subject of several research analyst reports. BidaskClub raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Piper Jaffray set a $25.00 price target on shares of Sangamo Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Zacks Investment Research downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Wedbush reaffirmed a “neutral” rating and issued a $6.00 price target on shares of Sangamo Therapeutics in a research note on Monday, February 12th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $20.83.

The company has a debt-to-equity ratio of 0.13, a quick ratio of 5.54 and a current ratio of 5.54. The stock has a market capitalization of $1,536.83, a P/E ratio of -23.21 and a beta of 2.80.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.03. The company had revenue of $13.08 million during the quarter, compared to the consensus estimate of $11.10 million. Sangamo Therapeutics had a negative net margin of 149.23% and a negative return on equity of 31.44%. The firm’s revenue for the quarter was up 46.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.14) earnings per share. equities analysts anticipate that Sangamo Therapeutics Inc will post -0.15 EPS for the current fiscal year.

In other news, Director Steven J. Mento sold 11,520 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $20.59, for a total transaction of $237,196.80. Following the completion of the sale, the director now directly owns 5,000 shares of the company’s stock, valued at $102,950. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Kathy Yi sold 5,000 shares of the business’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $19.83, for a total transaction of $99,150.00. Following the sale, the chief financial officer now directly owns 12,250 shares of the company’s stock, valued at $242,917.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 103,059 shares of company stock valued at $2,214,622. 5.50% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. boosted its holdings in Sangamo Therapeutics by 29.3% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 18,962 shares of the biopharmaceutical company’s stock worth $311,000 after purchasing an additional 4,300 shares during the last quarter. Nationwide Fund Advisors boosted its holdings in Sangamo Therapeutics by 13.5% during the third quarter. Nationwide Fund Advisors now owns 44,892 shares of the biopharmaceutical company’s stock worth $673,000 after purchasing an additional 5,337 shares during the last quarter. Swiss National Bank boosted its holdings in Sangamo Therapeutics by 3.9% during the fourth quarter. Swiss National Bank now owns 142,460 shares of the biopharmaceutical company’s stock worth $2,336,000 after purchasing an additional 5,400 shares during the last quarter. California State Teachers Retirement System boosted its holdings in Sangamo Therapeutics by 5.0% during the third quarter. California State Teachers Retirement System now owns 132,741 shares of the biopharmaceutical company’s stock worth $1,991,000 after purchasing an additional 6,360 shares during the last quarter. Finally, Great West Life Assurance Co. Can boosted its holdings in Sangamo Therapeutics by 150.3% during the third quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock worth $182,000 after purchasing an additional 7,667 shares during the last quarter. 65.16% of the stock is owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply